

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

**VOLUNTARY ANNOUNCEMENT
COMPLETION OF ACQUISITION OF 100% OF
THE ENTIRE ISSUED SHARES OF
CUSTOMARRAY, INC.**

This is a voluntary announcement made by the Company.

Reference is made to the announcement dated 27 December 2017 of the Company in relation to the Acquisition of the Target Company (the “**Announcement**”). Unless the context otherwise requires, the terms used in this announcement shall have the same meanings as those defined in the Announcement.

On 11 January 2018, the Company was informed by the Buyer that (i) the conditions precedent set out in the Stock Purchase Agreement have been satisfied and (ii) 100% of the entire issued shares of the Target Company have been transferred to the Buyer. The Board of Directors of the Company is pleased to announce that the Acquisition is complete.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 12 January 2018

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*